Výsledky vyhledávání - "Amy L. Boland"

Testosterone deficiency and quality of life in Australasian testicular cancer survivors: a prospective cohort study

Autor: Martin R. Stockler, Amy L. Boland, Damien Thomson, Peter Grimison, A. McDonald, New Zealand Urogenital, N. Singhal, Guy C. Toner, Brent O'Carrigan, C. Underhill, Fritha J. Hanning, Ian D. Davis, Hayley S. Whitford, P. Clingan, Ian N. Olver, M. Fournier

Publikováno v: Internal Medicine Journal. 44:813-817

This is the first prospective study in a contemporary Australian/New Zealand population to determine the prevalence of testosterone deficiency in testicular cancer survivors at 12 months from treatment, and any association with poorer quality of life

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a4e448fd975cf1aa0d5c70c977835d6
https://doi.org/10.1111/imj.12500

Zobrazit plný text záznamu

Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis

Autor: R. John Simes, Sonia Yip, Chris Brown, Niall C. Tebbutt, G. Mark Jeffrey, John Zalcberg, Guy van Hazel, Ray M. Lowenthal, Val Gebski, Amy L. Boland, David Goldstein, M. Buck, David Ransom, Stephen Clarke

Publikováno v: European Journal of Cancer. 47:1826-1836

Background Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5-fluorouracil or alone in patients previously treated with a fluoropyrimi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d58a1324d35af5a9abd28fc25fc78e3c
https://doi.org/10.1016/j.ejca.2011.04.024

Zobrazit plný text záznamu

Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Autor: Martin R. Stockler, Peter Grimison, Paul Vasey, Mark Rosenthal, Michael Friedlander, Mark D. Chatfield, Guy C. Toner, Amy L. Boland, Val Gebski, Howard Gurney, Baerin Houghton, Craig R. Lewis, Damien Thomson, Sarah E. Wong, Ganessan Kichenadasse, N. Singhal

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 25(1)

Background This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerability and activity of accelerated bleomycin, etoposide and cisplatin (BEP) as first-line chemotherapy for metastatic germ cell tumours. Patients and meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb7ae88ab3e4cddabf2f9eabf815b1fe
https://pubmed.ncbi.nlm.nih.gov/24356618

Zobrazit plný text záznamu

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy

Autor: Martin R. Stockler, Craig Underhill, Mark D. Chatfield, Rosemary Harrup, Ganessan Kichenadasse, Nimit Singhal, Guy C. Toner, Peter Grimison, Ian D. Davis, Damien Thomson, Ian N. Olver, Ann McDonald, Amy L. Boland, Val Gebski

Purpose: The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy. Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f7711ffa39bd5ae633bf075b5222505
https://hdl.handle.net/1959.8/162988

Zobrazit plný text záznamu

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial

Autor: Ian N. Olver, Paul Craft, Damien Thomson, Guy C. Toner, Howard Gurney, Craig R. Lewis, Amy L. Boland, Peter Grimison, Martin R. Stockler, Michael Boyer, John A. Levi, Val Gebski, Vernon Harvey, R. John Simes

Publikováno v: Journal of the National Cancer Institute. 102(16)

Background: The Australian and New Zealand Germ Cell Trials Group conducted a multicenter randomized phase III trial in men with good-prognosis germ cell tumors of two standard chemotherapy regimens that contained bleomycin, etoposide, and cisplatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44a1f2bfc9c28d87679f9754a906cd41
https://pubmed.ncbi.nlm.nih.gov/20836283

Zobrazit plný text záznamu

Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials

Publikováno v: Web of Science

4531 Background: Standard chemotherapy for advanced germ cell tumors is 3-weekly BEP (bleomycin, etoposide, cisplatin). 5-year overall survival is > 90% in good risk disease, but only ~80% in intermediate and ~ 60% in poor risk disease. Accelerated v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74683a18b7f6600488eeaaf0a9c96512
https://doi.org/10.1200/jco.2012.30.15_suppl.4531

Zobrazit plný text záznamu

Corrigendum to 'Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis' [Eur J Cancer 47 (12) (2011) 1826–1836]

Autor: Amy L. Boland, Chris Brown, R. John Simes, Ray M. Lowenthal, Sonia Yip, G. Mark Jeffrey, John Zalcberg, Guy van Hazel, David Goldstein, Niall C. Tebbutt, Val Gebski, M. Buck, David Ransom, Stephen Clarke

Publikováno v: European Journal of Cancer. 48:407

Stephen J. Clarke *, Sonia Yip , Chris Brown , Guy A. van Hazel , David T. Ransom , David Goldstein , G. Mark Jeffrey , Niall C. Tebbutt , Martin Buck , Raymond M. Lowenthal , Amy Boland , Val Gebski , John Zalcberg , R. John Simes , on behalf of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::73c60796d781efa0e67aeb21a5183fdd
https://doi.org/10.1016/j.ejca.2011.12.001

Zobrazit plný text záznamu

Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial

Autor: Martin R. Stockler, Mark D. Chatfield, Nimit Singhal, Michael Friedlander, New Zealand Urogenital, Paul Vasey, Amy L. Boland, Howard Gurney, Meredith B. Rosenthal, Damien Thomson, Ganessan Kichenadasse, Craig R. Lewis, Baerin Houghton, Peter Grimison, Shirley Wong, Val Gebski, G. C. Toner

Publikováno v: Journal of Clinical Oncology. 29:4561-4561

4561 Background: Standard chemotherapy for advanced germ cell tumors is BEP (bleomycin, etoposide, cisplatin). 5-year survival is > 90% in good-risk disease, but only ~80% in intermediate and ~ 60%...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b426f6bc0fda766ce5fe71256d016a18
https://doi.org/10.1200/jco.2011.29.15_suppl.4561

Zobrazit plný text záznamu

Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumors: Updated analysis of a randomized trial with 8 years follow-up

Autor: Amy L. Boland, M. R. Stockler, Howard Gurney, Australia, Guy C. Toner, P. S. Grimison, Val Gebski, V. J. Harvey, C. R. Lewis, Damien Thomson, Ian N. Olver

Publikováno v: Journal of Clinical Oncology. 27:5016-5016

5016 Background: We performed a multicentre randomised trial for good-prognosis germ-cell tumours of two standard chemotherapy regimens containing bleomycin (B), etoposide (E) and cisplatin (P). Accrual was stopped early, after interim analysis with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8de4f1ed626849855b36170ecd513550
https://doi.org/10.1200/jco.2009.27.15_suppl.5016

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání